Loading patent…
AssigneeLumiere Therapeutics Co., Ltd.
InventorsBohong CHEN, Yang HU, Yulin YU, Wenqiong TAN, Shaoyun LIN, Wenchang XU, Youyu WU, Xiaojie MA, Jiajun YU, Jinshuai SUN
Estimating the term…
Disclosed herein are a Cas12i polypeptide and use thereof in a CRISPR-Cas system. Specifically disclosed herein are a Cas12i polypeptide, a Cas12i fusion polypeptide, a guide RNA, a complex formed by the Cas12i polypeptide or fusion polypeptide with the guide RNA, a nucleic acid, a vector, a vector system, a delivery system, a kit, a composition, and a method for modifying a nucleic acid using the components described above.
An engineered chimeric Cas12i polypeptide comprising a Nuc domain, wherein the Nuc domain is derived from a Nuc domain of a first Cas12i polypeptide, a non-Nuc domain moiety of the engineered chimeric Cas12i polypeptide is derived from a non-Nuc domain moiety of a second Cas12i polypeptide, the first Cas12i polypeptide has no more than 80% sequence identity to the second Cas12i polypeptide, and the engineered chimeric Cas12i polypeptide is capable of binding to a nucleic acid and optionally cleaving the nucleic acid.
A nucleic acid, comprising a guide RNA or a nucleotide sequence encoding the guide RNA, wherein the guide RNA comprises a repeat segment comprising the nucleotide sequence set forth in any one of SEQ ID NOs:
Dependencies are inferred from the claim text.